Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Washington Court Hotel

25 sep 2013 8:00 a.m. - 27 sep 2013 5:00 p.m.

525 New Jersey Avenue NW, Washington, DC 20001

DIA/FDA Oligonucleotide-based Therapeutics Conference

Session Chair(s)

Anthony  Scozzari

Anthony Scozzari

VP, Development Chemistry & Manufacturing

Ionis Pharmaceuticals, Inc., United States

Speaker(s)

Daniel  Capaldi, PHD

Process Development and Validation

Daniel Capaldi, PHD

Ionis Pharmaceuticals, Inc, United States

Vice President, Analytical and Process Development

Claus  Rentel, PHD

Establishing Specification Limits for Phosphorothioate Oligonucleotides

Claus Rentel, PHD

Ionis Pharmaceuticals, Inc., United States

Vice President, Analytical Development and Quality Control

Daniel  Capaldi, PHD

Panelist

Daniel Capaldi, PHD

Ionis Pharmaceuticals, Inc, United States

Vice President, Analytical and Process Development

Claus  Rentel, PHD

Panelist

Claus Rentel, PHD

Ionis Pharmaceuticals, Inc., United States

Vice President, Analytical Development and Quality Control

Ramesh  Raghavachari, PHD

Panelist

Ramesh Raghavachari, PHD

FDA, United States

Supervisor, Unit 3/DPQA IV/OPQA I/OPQ/CDER

Fran  Wincott, PHD

Panelist

Fran Wincott, PHD

Wincott & Associates, LLC, United States

President

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.